Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : 2009 Biotech Charity Contest -- Ignore unavailable to you. Want to Upgrade?

To: BulbaMan who wrote (210)	4/15/2009 3:54:22 PM
From: technetium	Respond to of 418

GILD buys CVTX for $20 cash per share. Rebalance away... :-) "FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq:GILD) announced today the successful completion of its cash tender offer for all of the outstanding shares of common stock of CV Therapeutics, Inc. (Nasdaq:CVTX). The offer expired as scheduled at one minute following 11:59 p.m., New York City time (midnight), on April 14, 2009." The offer expired as scheduled at one minute following 11:59 p.m., New York City time (midnight)... No confusion here as to whether it's 12 AM, 12 PM, or midnight.

To: BulbaMan who wrote (210)	4/15/2009 7:18:19 PM
From: keokalani'nui	Read Replies (4) \| Respond to of 418

Hi Bulba, Here are my share counts after allocating DNA shares. I used 3/25 closing prices. As always, thanks for hosting and many updates. arna 1,719.21 aryx 8,773.89 crxl 263.67 dna - dsco 5,426.81 gtxi 750.12 nbix 7,733.83 pozn 2,437.19 If anyone had a slug of dndn there could be a change in rank this week.

To: BulbaMan who wrote (210)	4/17/2009 5:31:35 PM
From: BulbaMan	Read Replies (3) \| Respond to of 418

4/17/09 update Although the Nasdaq Biotech Index underperformed the Nasdaq Composite Index for the week, the Contest median did manage to cut its CYTD (Contest Year To Date) loss and it continues to outperform the NBI. At Friday's close the NCI was up 6.46% CYTD (vs. up 5.15% CYTD at its 4/9/09 close), the NBI was down -6.07% CYTD (vs. down -4.77% CYTD at its 4/9/09 close), while the Contest median was down -2.52% CYTD (vs. down -4.00% CYTD at its 4/9/09 close). Powered by Dendreon dynamite, GEORGIA's portfolio rocketed into the Contest lead with three other portfolios closely bunched in the next three places. The CYTD percentages were: GEORGIA up 33.99%, GENE up 31.37%, PRAVN up 30.07% and RKRW up 29.05%. At Friday's close, 13 of the 32 Contest portfolios were in the black and 19 of the 32 were beating the NBI. I've reallocated the proceeds of Gilead's $20 buyout of CVTX, using today's closing prices. Sorry, but no update next week as I'll be traveling. Have a wonderful weekend folks! Below is the Top Ten list on 4/17/09: 4/17/09 Rank Name Profit/Loss 1 GEORGIA 33,988 2 GENE 31,370 3 PRAVN 30,073 4 RKRW 29,054 5 BULBA 18,440 6 ASHLEY 10,728 7 ENZYME 10,337 8 WILDER 9,021 9 TECHNET 8,115 10 SCARAM 6,820 (All corrections, especially adjustments for splits, greatly appreciated.)